Nolato AB (publ) (NOLA_B) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to today's presentation with Nolato. With us presenting today, we have the CEO, Christer Wallquist, and CFO, Per-Ola Holmström. If you have any questions and you're calling in, please press star nine to raise your hand and then star six to mute yourself when it's your turn to speak. You can also submit your written questions via the form located to the right. And with that said, please go ahead with your presentation. Thank you and welcome to the presentation of Nolato's first quarter 2025. This is Chris DeWalkwist speaking. If we summarize the quarter, we had similar sales as comparison quarter, but with a very strong increase of our margins amounting to 11% as a total. creating an EBITDA on 271 million. We saw growth within the medical, but slightly lower sales for engineered solution due to the automotive sector. If we look on the margins, we strengthened the margins in both business areas, but particularly strong performance for medical solutions. Still, we have a very strong financial position with net financial liabilities in relation to adjusted operating profit of 0.5 times. Moving to page three in the presentation deck, looking at the two parts of our business, medical solution, now correspondent to 57% of our total sales, and engineered solution, 43% of the overall sales of the group. Jumping into medical solutions, starting with that, sales amounted to just below 1.4 billion in the quarter. And you can also see the continuous growth of the business area over the last 20 years on the graph. Moving to page five in the presentation deck, splitting up the medical sales in different focus product areas. During this quarter, we saw growth within the drug delivery part of the business. And other than that, minor changes around the different part...